BlackRock’s Moleculin Biotech MBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.37K | Hold |
491
| – | – | ﹤0.01% | 5548 |
|
|
2026
Q1 | $1.12K | Sell |
491
-4
| -0.8% | -$13 | ﹤0.01% | 5550 |
|
|
2025
Q4 | $1.64K | Hold |
495
| – | – | ﹤0.01% | 5400 |
|
|
2025
Q3 | $6.56K | Hold |
495
| – | – | ﹤0.01% | 5249 |
|
|
2025
Q2 | $3.74K | Hold |
495
| – | – | ﹤0.01% | 5286 |
|
|
2025
Q1 | $12.1K | Hold |
495
| – | – | ﹤0.01% | 5162 |
|
|
2024
Q4 | $21K | Sell |
495
-4
| -0.8% | -$242 | ﹤0.01% | 5094 |
|
|
2024
Q3 | $35.4K | Hold |
499
| – | – | ﹤0.01% | 4872 |
|
|
2024
Q2 | $43.9K | Hold |
499
| – | – | ﹤0.01% | 4890 |
|
|
2024
Q1 | $73.7K | Sell |
499
-5
| -1% | -$1.07K | ﹤0.01% | 4799 |
|
|
2023
Q4 | $162K | Sell |
504
-19
| -4% | -$3.94K | ﹤0.01% | 4691 |
|
|
2023
Q3 | $83.9K | Hold |
523
| – | – | ﹤0.01% | 4897 |
|
|
2023
Q2 | $114K | Sell |
523
-167
| -24% | -$44.1K | ﹤0.01% | 4872 |
|
|
2023
Q1 | $248K | Buy |
690
+5
| +0.7% | +$2.19K | ﹤0.01% | 4715 |
|
|
2022
Q4 | $272K | Sell |
685
-16
| -2% | -$6.75K | ﹤0.01% | 4766 |
|
|
2022
Q3 | $278K | Sell |
701
-6
| -0.8% | -$3.48K | ﹤0.01% | 4893 |
|
|
2022
Q2 | $384K | Sell |
707
-1
| -0.1% | -$582 | ﹤0.01% | 4859 |
|
|
2022
Q1 | $472K | Sell |
708
-24
| -3% | -$13.8K | ﹤0.01% | 4884 |
|
|
2021
Q4 | $510K | Buy |
732
+11
| +2% | +$9.76K | ﹤0.01% | 4864 |
|
|
2021
Q3 | $812K | Sell |
721
-18
| -2% | -$21K | ﹤0.01% | 4614 |
|
|
2021
Q2 | $1.02M | Buy |
739
+101
| +16% | +$138K | ﹤0.01% | 4508 |
|
|
2021
Q1 | $977K | Buy |
638
+619
| +3,258% | +$1.13M | ﹤0.01% | 4507 |
|
|
2020
Q4 | $34K | Hold |
19
| – | – | ﹤0.01% | 4716 |
|
|
2020
Q3 | $36K | Hold |
19
| – | – | ﹤0.01% | 4646 |
|
|
2020
Q2 | $42K | Sell |
19
-43
| -69% | -$102K | ﹤0.01% | 4602 |
|
|
2020
Q1 | $85K | Buy |
62
+1
| +2% | +$1.7K | ﹤0.01% | 4381 |
|
|
2019
Q4 | $127K | Buy |
61
+14
| +30% | +$32.8K | ﹤0.01% | 4402 |
|
|
2019
Q3 | $118K | Sell |
47
-3
| -6% | -$7.75K | ﹤0.01% | 4414 |
|
|
2019
Q2 | $141K | Buy |
50
+29
| +138% | +$78.8K | ﹤0.01% | 4419 |
|
|
2019
Q1 | $39K | Sell |
21
-2
| -9% | -$5.96K | ﹤0.01% | 4510 |
|
|
2018
Q4 | $54K | Hold |
23
| – | – | ﹤0.01% | 4465 |
|
|
2018
Q3 | $83K | Buy |
23
+1
| +5% | +$3.77K | ﹤0.01% | 4483 |
|
|
2018
Q2 | $89K | Buy |
+22
| New | +$90.1K | ﹤0.01% | 4475 |
|
|
2017
Q2 | – | Sell |
-8
| Closed | -$21K | – | 5072 |
|
|
2017
Q1 | $21K | Buy |
+8
| New | +$28K | ﹤0.01% | 4610 |
|
Other funds holding MBRX
VCM
VFT
TRCT
SS
DB
CFO
BlackRock's MBRX Position: Q2 2026 in Review
BlackRock held its Moleculin Biotech (MBRX) position steady in Q2 2026 at 491 shares worth $1.37K. The position accounts for ﹤0.01% of the portfolio, ranked #5548.
BlackRock first reported a position in MBRX in Q1 2017 and has held it in 34 quarters since. The position peaked at $1.02M in Q2 2021. 11 funds tracked by Wall St. Rank hold MBRX as of Q2 2026.
- BlackRock held 491 shares of Moleculin Biotech worth $1.37K as of Q2 2026.
- BlackRock left its Moleculin Biotech share count unchanged in Q2 2026.
- Moleculin Biotech made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5548 holding.
- BlackRock first reported a position in Moleculin Biotech in Q1 2017 and has held it in 34 quarters since.
- BlackRock's Moleculin Biotech position peaked at $1.02M in Q2 2021.
- 11 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.